TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07745361: Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

Sponsor: Monte Rosa Therapeutics, Inc · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 25 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,541,000

Rescue Site Savings

+$1,663,200

Unlock Full NCT07745361 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07745361 Rescue Dossier →